Azitra Inc ( (AZTR)) has shared an announcement. Azitra Inc., a clinical-stage biopharmaceutical company specializing in precision dermatology therapies for severe skin conditions such as Netherton ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

JSKN021 is a “2-in-1” dual payload bispecific ADC targeting EGFR and HER3. By leveraging glycan-specific conjugation technology, it precisely and quantitatively links two different cytotoxic payloads ...

For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over ...

Second clinical candidate from HUTCHMED’s next-generation ATTC platform — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) ...

The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.

TD Cowen 46th Annual Health Care Conference March 2, 2026 2:30 PM ESTCompany ParticipantsDave Gancarz - Chief Business ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...